Literature DB >> 31930396

Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.

Mingxin Shi1, Allison E Whorton1, Nikola Sekulovski1, Marilène Paquet2, James A MacLean1, Yurong Song3, Terry Van Dyke3, Kanako Hayashi1.   

Abstract

Ovarian cancer (OvCa) remains the most common cause of death from gynecological malignancies. Genetically engineered mouse models have been used to study initiation, origin, progression, and/or mechanisms of OvCa. Based on the clinical features of OvCa, we examined a quadruple combination of pathway perturbations including PTEN, TRP53, RB1, and/or CDH1. To characterize the cancer-promoting events in the ovarian surface epithelium (OSE), Amhr2cre/+ mice were used to ablate floxed alleles of Pten, Trp53, and Cdh1, which were crossed with TgK19GT121 mice to inactivate RB1 in KRT19-expressing cells. Inactivation of PTEN, TRP53, and RB1 with or without CDH1 led to the development of type I low-grade OvCa with enlarged serous papillary carcinomas and some high-grade serous carcinomas (HGSCs) in older mice. Initiation of epithelial hyperplasia and micropapillary carcinoma started earlier at 1 month in the triple mutations of Trp53, Pten, and Rb1 mice as compared to 2 months in quadruple mutations of Trp53, Pten, Rb1, and Cdh1 mice, whereas both genotypes eventually developed enlarged proliferating tumors that invaded into the ovary at 3-4 months. Mice with triple and quadruple mutations developed HGSC and/or metastatic tumors, which disseminated into the peritoneal cavity at 4-6 months. In summary, inactivation of PTEN, TRP53, and RB1 initiates OvCa from the OSE. Additional ablation of CDH1 further increased persistence of tumor dissemination and ascites fluid accumulation enhancing peritoneal metastasis.
© The Author(s) 2020. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CDH1; PTEN; RB1 and epithelial ovarian cancer; TRP53

Year:  2020        PMID: 31930396      PMCID: PMC7305658          DOI: 10.1093/biolre/ioaa008

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  32 in total

1.  Ovulation and risk of epithelial ovarian cancer.

Authors:  David M Purdie; Christopher J Bain; Victor Siskind; Penelope M Webb; Adèle C Green
Journal:  Int J Cancer       Date:  2003-03-20       Impact factor: 7.396

Review 2.  Genetically-defined ovarian cancer mouse models.

Authors:  Patrice J Morin; Ashani T Weeraratna
Journal:  J Pathol       Date:  2016-01       Impact factor: 7.996

3.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

4.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

5.  PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.

Authors:  Angela Russo; Austin A Czarnecki; Matthew Dean; Dimple A Modi; Daniel D Lantvit; Laura Hardy; Seth Baligod; David A Davis; Jian-Jun Wei; Joanna E Burdette
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

6.  Wt1 directs the lineage specification of sertoli and granulosa cells by repressing Sf1 expression.

Authors:  Min Chen; Lianjun Zhang; Xiuhong Cui; Xiwen Lin; Yaqiong Li; Yaqing Wang; Yanbo Wang; Yan Qin; Dahua Chen; Chunsheng Han; Bin Zhou; Vicki Huff; Fei Gao
Journal:  Development       Date:  2016-11-25       Impact factor: 6.868

7.  A causal role for E-cadherin in the transition from adenoma to carcinoma.

Authors:  A K Perl; P Wilgenbus; U Dahl; H Semb; G Christofori
Journal:  Nature       Date:  1998-03-12       Impact factor: 49.962

8.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.

Authors:  Andrea Flesken-Nikitin; Kyung-Chul Choi; Jessica P Eng; Elena N Shmidt; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

9.  Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.

Authors:  J S Richards; H-Y Fan; Z Liu; M Tsoi; M-N Laguë; A Boyer; D Boerboom
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

10.  E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.

Authors:  U H Frixen; J Behrens; M Sachs; G Eberle; B Voss; A Warda; D Löchner; W Birchmeier
Journal:  J Cell Biol       Date:  1991-04       Impact factor: 10.539

View more
  4 in total

1.  Regulation of PTEN and ovarian cancer progression by an E3 ubiquitin ligase RBCK1.

Authors:  Guanghui Wang; Zi Zhuang; Siyuan Shen; Fan Yang; Zhiyuan Jiang; Ziping Liu; Tianshi Wang; Lei Hua
Journal:  Hum Cell       Date:  2022-02-16       Impact factor: 4.374

2.  Progestin Significantly Inhibits Carcinogenesis in the Mogp-TAg Transgenic Mouse Model of Fallopian Tube Cancer.

Authors:  Omar L Nelson; Rebecca Rosales; Jane M Turbov; Larry G Thaete; J Mark Cline; Gustavo C Rodriguez
Journal:  Cancer Prev Res (Phila)       Date:  2021-11-29

Review 3.  Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).

Authors:  Ling Yang; Hong-Jian Xie; Ying-Ying Li; Xia Wang; Xing-Xin Liu; Jia Mai
Journal:  Oncol Rep       Date:  2022-02-25       Impact factor: 3.906

Review 4.  Harnessing preclinical models for the interrogation of ovarian cancer.

Authors:  Tianyu Qin; Junpeng Fan; Funian Lu; Li Zhang; Chen Liu; Qiyue Xiong; Yang Zhao; Gang Chen; Chaoyang Sun
Journal:  J Exp Clin Cancer Res       Date:  2022-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.